Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune‐mediated inflammatory diseases: A European retrospective observational study

BACKGROUND AND AIMS: Few data are available regarding the combination of biologics or small molecules in inflammatory bowel disease (IBD) patients. We report safety and efficacy of such combinations through a retrospective multicentre series. METHODS: Combination therapy was defined as the concomita...

Descripción completa

Detalles Bibliográficos
Autores principales: Goessens, Laurent, Colombel, Jean‐Frédéric, Outtier, An, Ferrante, Marc, Sabino, Joao, Judge, Ciaran, Saeidi, Reza, Rabbitt, Louise, Armuzzi, Alessandro, Domenech, Eugeni, Michalopoulos, George, Cremer, Anneline, García‐Alonso, Francisco Javier, Molnar, Tamas, Karmiris, Konstantinos, Gecse, Krisztina, Van Oostrom, Joep, Löwenberg, Mark, Farkas, Klaudia, Atreya, Raja, Ribaldone, Davide Giuseppe, Selinger, Christian, Hoentjen, Frank, Bihin, Benoit, Sebastian, Shaji, Rahier, Jean‐François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672088/
https://www.ncbi.nlm.nih.gov/pubmed/34694746
http://dx.doi.org/10.1002/ueg2.12170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672088/
https://www.ncbi.nlm.nih.gov/pubmed/34694746
http://dx.doi.org/10.1002/ueg2.12170

Ejemplares similares